An economic model to value companion diagnostics in non-small-cell lung cancer

Personalized Medicine

Volumn 10, Issue 2, 2013, Pages 139-147

  Lieberthal, Robert D ^a   Dudash, Kellie ^a,b   Axelrod, Rita ^c   Goldfarb, Neil I ^a,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b XCENDA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Greater Philadelphia Business Coalition on Health   (United States)

Author keywords

companion diagnostic; cost effectiveness analysis; decision analysis; molecular therapies; non small cell lung cancer

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LUNG NON SMALL CELL CANCER; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 84874627160     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.7     Document Type: Article

References (22)

1. Bradbury PA, Tu D, Seymour L et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J. Natl Cancer Inst. 102(5), 298-306 (2010).
2. Warren JL, Yabroff KR, Meekins A et al. Evaluation of trends in the cost of initial cancer treatment. J. Natl Cancer Inst. 100(12), 888-897 (2008).
3. Bates S. Progress towards personalized medicine. Drug Discov. Today 15(3-4), 115-120 (2010).
4. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat. Biotechnol. 24(8), 985-995 (2006).
5. Bell DW, Lynch TJ, Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23(31), 8081-8092 (2005).
6. Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30(8), 863-870 (2012).
7. Becker R, Mansfield E. Companion diagnostics. Clin. Adv. Hematol. Oncol. 8(7), 478-479 (2010).
8. Ferrara J. Personalized medicine: challenging pharmaceutical and diagnostic company business models. Mcgill J. Med. 10(1), 59-61 (2007).
9. Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 27(36), 6251-6266 (2009).
10. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med. 359(13), 1367-1380 (2008).
11. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12(11), 1004-1012 (2011).
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
13. VanHorn N, Bentley K. National Fee Analyzer 2010: Charge Data for Evaluating Fees Nationally, Ingenix, USA (2009).
14. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer 106(6), 1100-1106 (2012).
15. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N. Engl. J. Med. 364(21), 2060-2065 (2011).
16. Yu J, Kane S, Wu J et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin. Cancer Res. 15(9), 3023-3028 (2009).
17. Janne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 12(14), 4416S-4420S (2006).
18. Janne PA, Wang XF, Socinski MA et al. Randomized Phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J. Clin. Oncol. 28(15s), Abstract 7503 (2010).
19. Ramsey SD, Martins RG, Blough DK et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am. J. Manag. Care 14(5), 297-306 (2008).
20. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
21. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010).
22. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).